This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Corcept Therapeutics: Pump Up the Volume

MENLO PARK, Calif. ( TheStreet) -- Corcept Therapeutics (CORT - Get Report) shares rallied sharply higher Tuesday on heavy volume after the company said it plans raise about $18 million by selling stock and options to institutional investors.

Corcept Therapeutics said it has agreed to sell an aggregate of up to approximately 12.6 million units for $1.43 per unit. Each unit consists of one share of common stock and one warrant to purchase 0.35 shares of common stock at a per share exercise price of $1.66.

Corcept said it intends to use the net proceeds from the offering to fund the completion of enrollment in its Phase 3 trial of its Corlux drug for the treatment of Cushing's Syndrome and the submission of its Cushing's Syndrome NDA, as well as for general corporate purposes, including working capital.

Corcept Therapeutics shares were jumping by 30 cents, or 21.7%, to $1.68. Earlier in the session, the stock touched an intraday and new 52-week high of $2. More than 372,000 shares changed hands by 3:30 p.m. EDT Tuesday, compared to the stock's 50-day average daily volume of 19,000, according to the Nasdaq.

Corcept, which develops drugs to treat severe metabolic and psychiatric disorders, has a 10.8 million-share float with only 2,910 shares short as of Sept. 10, according to Yahoo! Finance. More than 65% of the company's shares are held by insiders with another 4.6% owned by institutions.

Read more about today's high-volume stocks in earlier "Pump Up the Volume" posts.

-- Written by Robert Holmes in New York.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CORT $3.86 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs